Pathophysiology, noninvasive diagnostics and emerging personalized treatments for metabolic associated liver diseases
Metabolic Dysfunction-Associated Steatohepatitis (MASH), the advanced stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a leading cause of chronic liver disease, driving cirrhosis, liver cancer, and mortality. With metabolic, genetic, and environmental factors at play, early detection and treatment are critical. This review highlights the latest breakthroughs in MASH pathophysiology, cost-effective noninvasive diagnostics, and emerging therapies, emphasizing the urgency of accessible solutions to combat this growing global health crisis.
Authors
- Liang Qiao (ORCID: https://orcid.org/0000-0002-4723-8935)
- Fatema Zerin Farhana (ORCID: https://orcid.org/0000-0001-8031-0620)
- Allen G. Ross (ORCID: https://orcid.org/0000-0002-2329-0907)
- Muhammad J. A. Shiddiky (ORCID: https://orcid.org/0000-0003-4526-4109)
- Kevin M. Koo (ORCID: https://orcid.org/0000-0002-2652-1985)
- Farjana Haque (ORCID: https://orcid.org/0000-0001-8297-2652)
- Milkiyas Toru Tantu
Institutions
- Charles Sturt University (AU)
- The University of Queensland (AU)
- Westmead Hospital (AU)
- Westmead Institute (AU)
- Westmead Institute for Medical Research (AU)
Publication Details
- Journal
- npj gut and liver.
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1038/s44355-025-00030-2
- Citations
- 9
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 12.19